Alternative Start Sites Downstream of Non-Sense Mutations Drive Antigen Presentation and Tolerance Induction to C-Terminal Epitopes

The Journal of Immunology : Official Journal of the American Association of Immunologists
Scott N AshleyJames M Wilson

Abstract

CTL responses to the transgene product remain an active area of concern for the gene therapy field. A patient's underlying genetic mutation may influence the qualitative nature of these potentially destructive T cell responses. Individuals with a mutation that introduces a premature termination codon (PTC) that prevents synthesis of the full-length peptide are considered more likely to mount a transgene-specific T cell response because of a lack of immune tolerance to C-terminal epitopes as a consequence of absent endogenous Ag presentation. In this article, we demonstrate that a human ornithine transcarbamylase gene containing various PTC-inducing non-sense mutations is able to generate and present epitopes downstream of the termination codon. Generation of these epitopes occurs primarily from alternative translation start sites downstream of the stop codon. Furthermore, we show that expression of these genes from adeno-associated virus vectors in C57BL/6 mice is able to induce peripheral tolerance to epitopes downstream of the PTC. These results suggest that, despite the lack of full-length endogenous protein, patients with PTC-inducing non-sense mutations may still present T cell epitopes downstream of the premature terminat...Continue Reading

References

Aug 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·M GrompeC T Caskey
Apr 24, 1987·Cell·J W KapplerP Marrack
Feb 1, 1996·Human Genetics·E Oppliger LeibundgutS Liechti-Gallati
Mar 1, 1996·Science·P E FieldsF W Fitch
Jan 1, 1996·Human Mutation·E O Oppliger LeibundgutS Liechti-Gallati
Sep 8, 2001·Molecular Therapy : the Journal of the American Society of Gene Therapy·R W HerzogC D Lothrop
Sep 8, 2001·Molecular Therapy : the Journal of the American Society of Gene Therapy·P A FieldsK A High
Dec 10, 2002·Annual Review of Immunology·Ronald H Schwartz
Sep 30, 2004·Gene Therapy·T H Nguyen, N Ferry
Mar 16, 2006·Proceedings of the National Academy of Sciences of the United States of America·Eric DobrzynskiRoland W Herzog
Jun 21, 2006·Human Mutation·Saori YamaguchiMendel Tuchman
Mar 14, 2007·Annual Review of Biochemistry·Yao-Fu ChangMiles F Wilkinson
Jun 21, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Maria P LimberisJames M Wilson
Nov 17, 2007·The Journal of Clinical Investigation·Shih-Wen LinHildegund C J Ertl
Jun 7, 2008·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·Alex V Kochetov
Apr 21, 2009·Nature Methods·Jacek R WiśniewskiMatthias Mann
Jul 16, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Ou CaoRoland W Herzog
Dec 30, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Brian P DolanJonathan W Yewdell
Sep 25, 2010·Nucleic Acids Research·Georgii A Bazykin, Alex V Kochetov
Oct 12, 2010·The New England Journal of Medicine·Jerry R MendellChristopher M Walker
Jan 14, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·Brian P DolanJonathan W Yewdell
Mar 11, 2011·Cellular and Molecular Life Sciences : CMLS·Shelley R Starck, Nilabh Shastri
Jun 29, 2011·Proceedings of the National Academy of Sciences of the United States of America·Sebastien ApcherRobin Fåhraeus
Nov 22, 2011·Autoimmunity Reviews·Danielle de VerteuilClaude Perreault
May 1, 2012·Nature Immunology·Leonid A PobezinskyAlfred Singer
Feb 6, 2013·PLoS Pathogens·Nathan P CroftAnthony W Purcell
Nov 1, 2013·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jeff D ColbertKenneth L Rock
Jan 28, 2014·Journal of Translational Medicine·Geoffrey L RogersRoland W Herzog
Apr 8, 2014·Proceedings of the National Academy of Sciences of the United States of America·Elliot GoodenoughLaurence C Eisenlohr
Jul 3, 2015·Frontiers in Immunology·Christine Riedhammer, Robert Weissert
Sep 24, 2015·Nature Reviews. Molecular Cell Biology·Søren Lykke-Andersen, Torben Heick Jensen
Feb 11, 2016·RNA Biology·Anna Vilborg, Joan A Steitz
Jun 21, 2016·Immunological Reviews·Shelley R Starck, Nilabh Shastri

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

AAV-based Gene Therapy

Adeno-associated virus (AAV)-based gene therapy is a biological vector that is being researched to be used as a potential therapeutic option. This gene therapy is designed to insert fragments of DNA into targeted cells to help treat diseases, such as hemophilia a. Discover the latest research on AAV-based gene therapy here.

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Related Papers

Molecular Therapy : the Journal of the American Society of Gene Therapy
Ekaterina BreousJames M Wilson
Proceedings of the National Academy of Sciences of the United States of America
Elliot GoodenoughLaurence C Eisenlohr
© 2022 Meta ULC. All rights reserved